CLPT Earnings

CLPT reported its earnings on 2026-05-13, showcasing a revenue of 12.13M against an estimate of 12.25M, resulting in a -1% surprise. The EPS was -0.32, surpassing the expected -0.28 by -14.29%. The stock experienced a 4.76% price change on the earnings day and a -8.37% change over the next five days, reflecting market reactions to the results.

Following CLPT's earnings announcement on 2026-05-13, the stock price moved by 4.76% on the day of the release. Over the subsequent five days, it saw a -8.37% change. Historically, CLPT's stock price tends to shift by an average of 7.14% in the 10 days leading up to earnings and 2.65% in the 10 days following, providing insight into potential market.

For 2026/Q2, analysts estimate CLPT's annual revenue to reach 13.40M, while the EPS is projected at -0.21. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between CLPT's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, CLPT's stock price typically moves by 7.14% in the 10 days before its earnings and 2.65% in the 10 days after. For the upcoming 2026/Q2 earnings, analysts expect an EPS of -0.21 and revenue of 13.40M.

The earnings call reflects a positive sentiment due to several factors: the integration of IRRAS Holdings, Inc. is expected to bring operational efficiencies, revenue increased by 15% YoY, and gross margins improved. Despite a net loss, the reduction compared to the previous year indicates financial health improvement. The company's strategic focus on cell and gene therapies, coupled with anticipated market growth, presents a strong outlook. However, risks like regulatory approval uncertainties and adoption rates are noted but do not outweigh the overall positive sentiment.